ENESTnd Update: Nilotinib versus Imatinib in Newly Diagnosed CML-CP


ENESTnd Update: Nilotinib versus Imatinib in Newly Diagnosed CML-CP
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/24/14)
Saglio G et al. ENESTnd update: Nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Proc ASH 2013;Abstract 92.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.